Correction: CDK1 is a synthetic lethal target for KRAS mutant tumours (PLoS ONE (2016) 11:2 (e0149099) DOI: 10.1371/journal.pone.0149099);CDK1 Is a synthetic lethal target for KRAS mutant tumours

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Costa Cabral, Sara ^a   Brough, Rachel ^a   Konde, Asha ^a   Aarts, Marieke ^a   Campbel, James ^a   Marinari, Eliana ^a   Riffell, Jenna ^a   Bardelli, Alberto ^b   Torrance, Christopher ^c,d   Lord, Christopher J ^a   Ashworth, Alan ^a,e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c Molecular Biotechnology Center   (United Kingdom)

^d Unity Campus   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; AZD5438; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; IMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RO 3306; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL TUMOR; CONTROLLED STUDY; DNA SEQUENCE; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; ONCOGENE K RAS; PANCREAS TUMOR; PROTEIN ANALYSIS; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LETHAL GENE; METABOLISM; MORTALITY; MUTATION; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, LETHAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIMIDINES; QUINOLINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978676921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0176578     Document Type: Erratum

References (47)

1. Nakano H, Yamamoto F, Neville C, Evans D, Mizuno T, Perucho M. Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proceedings of the National Academy of Sciences of the United States of America. 1984; 81(1):71-5. Epub 1984/01/01. PMID: 6320174; PubMed Central PMCID: PMC344612.
2. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science. 1984; 223 (4637):661-4. Epub 1984/02/17. PMID: 6695174.
3. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 7(4):295-308. Epub 2007/03/27. doi: nrc2109 [pii] doi: 10.1038/nrc2109 PMID: 17384584.
4. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. Epub 2011/10/14. doi: nrc3106 [pii] doi: 10.1038/nrc3106 PMID: 21993244; PubMed Central PMCID: PMC3632399.
5. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008; 9(7):517-31. Epub 2008/06/24. doi: nrm2438 [pii] doi: 10.1038/nrm2438 PMID: 18568040.
6. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17):4682-9. Epub 1989/09/ 01. PMID: 2547513.
7. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15(6):489-500. Epub 2009/05/30. doi: S1535-6108(09)00111-1 [pii] doi: 10.1016/j.ccr.2009.03. 022 PMID: 19477428; PubMed Central PMCID: PMC2743093.
8. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. Epub 2003/01/02. doi: 10.1038/nrc969nrc969 [pii]. PMID: 12509763.
9. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009; 27(7):1130-6. Epub 2009/01/07. doi: JCO.2008.19.8168 [pii] doi: 10.1200/ JCO.2008.19.8168 PMID: 19124802.
10. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010; 2010:150960. Epub 2010/07/10. doi: 10.1155/2010/150960 PMID: 20617134; PubMed Central PMCID: PMC2896632.
11. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. Epub 2006/ 04/19. doi: 66/8/3992 [pii] doi: 10.1158/0008-5472.CAN-06-0191 PMID: 16618717.
12. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27(12):2091-6. Epub 2009/02/04. doi: JCO.2009.21.9170 [pii] doi: 10.1200/JCO.2009.21.9170 PMID: 19188670.
13. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14(12):1351-6. Epub 2008/11/26. doi: nm.1890 [pii] doi: 10.1038/nm.1890 PMID: 19029981; PubMed Central PMCID: PMC2683415.
14. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462(7269):108-12. Epub 2009/10/23. doi: nature08460 [pii] doi: 10.1038/nature08460 PMID: 19847166; PubMed Central PMCID: PMC2783335.
15. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013; 23(1):121-8. Epub 2012/12/19. doi: S1535-6108(12)00487-4 [pii] doi: 10.1016/j.ccr. 2012.11.007 PMID: 23245996; PubMed Central PMCID: PMC3667614.
16. Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012; 149 (3):642-55. Epub 2012/05/01. doi: S0092-8674(12)00408-4 [pii] doi: 10.1016/j.cell.2012.02.059 PMID: 22541434.
17. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18(1):63-73. Epub 2010/07/09. doi: S1535-6108(10)00237-0 [pii] doi: 10.1016/j.ccr.2010. 05.025 PMID: 20609353.
18. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009; 137 (5):821-34. Epub 2009/06/06. doi: S0092-8674(09)00316-X [pii] doi: 10.1016/j.cell.2009.03.017 PMID: 19490892.
19. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012; 148(4):639-50. Epub 2012/02/22. doi: S0092-8674 (12)00102-X [pii] doi: 10.1016/j.cell.2011.12.033 PMID: 22341439; PubMed Central PMCID: PMC3291475.
20. Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM, et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene. 2010; 29 (33):4658-70. Epub 2010/06/22. doi: onc2010218 [pii] doi: 10.1038/onc.2010.218 PMID: 20562906.
21. Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012; 22(8):1227-45. Epub 2012/05/23. doi: cr201282 [pii] doi: 10.1038/cr.2012. 82 PMID: 22613949; PubMed Central PMCID: PMC3411175.
22. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477):548-51. Epub 2013/11/22. doi: nature12796 [pii] doi: 10.1038/nature12796 PMID: 24256730.
23. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell. 2011; 145(1):30-8. Epub 2011/04/05. doi: S0092-8674(11)00297-2 [pii] doi: 10.1016/j.cell.2011.03. 020 PMID: 21458666.
24. Lord CJ, Martin SA, Ashworth A. RNA interference screening demystified. J Clin Pathol. 2009; 62 (3):195-200. Epub 2009/01/08. doi: jcp.2008.058735 [pii] doi: 10.1136/jcp.2008.058735 PMID: 19126568; PubMed Central PMCID: PMC2652024.
25. Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, et al. Functional viability profiles of breast cancer. Cancer Discov. 2011; 1(3):260-73. Epub 2011/10/11. doi: 2159-8290.CD-11-0107 [pii] doi: 10.1158/2159-8290.CD-11-0107 PMID: 21984977; PubMed Central PMCID: PMC3188379.
26. Whitehead RH, Macrae FA, St John DJ, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. Journal of the National Cancer Institute. 1985; 74 (4):759-65. PMID: 3857372.
27. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(52):20864-9. Epub 2008/12/25. doi: 0808757105 [pii] doi: 10.1073/pnas.0808757105 PMID: 19106301; PubMed Central PMCID: PMC2634925.
28. Enserink JM, Kolodner RD. An overview of Cdk1-controlled targets and processes. Cell Div. 2010; 5:11. Epub 2010/05/15. doi: 1747-1028-5-11 [pii] doi: 10.1186/1747-1028-5-11 PMID: 20465793; PubMed Central PMCID: PMC2876151.
29. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005; 30 (11):630-41. Epub 2005/10/21. doi: S0968-0004(05)00276-8 [pii] doi: 10.1016/j.tibs.2005.09.005 PMID: 16236519.
30. Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005; 7(8):831-6. Epub 2005/07/12. doi: ncb1284 [pii] doi: 10.1038/ncb1284 PMID: 16007079.
31. Hu X, Moscinski LC. Cdc2: a monopotent or pluripotent CDK? Cell Prolif. 2011; 44(3):205-11. Epub 2011/05/04. doi: 10.1111/j.1365-2184.2011.00753.x PMID: 21535261.
32. Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007; 448(7155):811-5. Epub 2007/08/19. doi: nature06046 [pii] doi: 10.1038/nature06046 PMID: 17700700.
33. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004; 118(4):493-504. Epub 2004/08/ 19. doi: 10.1016/j.cell.2004.08.002S0092867404007500 [pii]. PMID: 15315761.
34. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491(7424):399-405. doi: 10.1038/nature11547 PMID: 23103869; PubMed Central PMCID: PMC3530898.
35. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(28):10660-5. doi: 10.1073/pnas.0600447103 PMID: 16818887; PubMed Central PMCID: PMC1502288.
36. Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009; 8(7):1856-66. Epub 2009/06/11. doi: 1535-7163. MCT-08-0836 [pii] doi: 10.1158/1535-7163.MCT-08-0836 PMID: 19509270.
37. Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem. 2010; 285(22):16978-90. doi: 10.1074/jbc.M109.096552 PMID: 20360007; PubMed Central PMCID: PMC2878026.
38. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(7):2415-20. doi: 10.1073/pnas.0712168105 PMID: 18272492; PubMed Central PMCID: PMC2268151.
39. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996; 271(14):8313-20. Epub 1996/04/05. PMID: 8626527.
40. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev. 2007; 17(1):60-5. Epub 2007/01/09. doi: S0959-437X(06)00242-5 [pii] doi: 10.1016/j.gde.2006.12.008 PMID: 17208431.
41. Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009; 8(2):324-32. doi: 10.1158/1535-7163.MCT-08-0890 PMID: 19174555.
42. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010; 9(8):2344-53. doi: 10. 1158/1535-7163.MCT-10-0324 PMID: 20663931.
43. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004; 3(11):1427-38. PMID: 15542782.
44. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nature medicine. 2007; 13(7):820-7. doi: 10.1038/nm1606 PMID: 17589519.
45. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. The Journal of experimental medicine. 2012; 209(4):679-96. doi: 10.1084/jem.20111512 PMID: 22430491; PubMed Central PMCID: PMC3328367.
46. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature medicine. 2011; 17(7):875-82. doi: 10.1038/nm. 377 PMID: 21706030; PubMed Central PMCID: PMC3272302.
47. Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, et al. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(31):12722-7. doi: 10.1073/ pnas.1202492109 PMID: 22802621; PubMed Central PMCID: PMC3411950.